tomy. The calcified lesion was compatible with inactive hydatid cyst. The cholecystectomy was finished uneventfully. Before sending the specimen to the pathology laboratory, we cut the wall of the gallbladder and saw the hydatid cysts (Figure 2). The patient was discharged on postoperative day one and placed on 400 mg/day albendazole treatment. Chronic inflammation and hydatid cyst membranes were observed in the histopathological evaluation of the gallbladder.

*E. granulosus* is responsible for hydatid disease, most commonly in the liver. This infection is usually seen in sheep- and cattle-raising regions. Cholangitis with obstructive jaundice is a rare and dreadful complication of hydatid cysts ruptured into the biliary tract. In addition to the diagnostic capabilities of ERCP, it is a treatment tool for obstructive pathologies of the bile duct (1,2). ERCP shows a cystobiliary relationship, and we did not observe any communication between the gallbladder and the calcified cystic lesion in the liver (3). A false-positive result of the serologic analysis should be kept in mind in patients with previous hydatid disease and no evidence of the disease currently (4). In this case, choledocholithiasis had been concluded as a main cause of the obstructive jaundice after ERCP preoperatively. In such patients, laparoscopic cholecystectomy is the best treatment strategy for preventing further cholangitis attacks. After surgery, macroscopic and pathologic findings revealed a cyst hydatid disease of the gallbladder in the patient, which is a very rare clinical entity (5). ERCP is used to diagnose and treat biliary pathologies. Removal of the gallbladder reduces further risks causing obstructive jaundice and helps in the definitive diagnosis.

REFERENCES


Metin ERTEM, Erman AYTAÇ, Zekeriya KARADUMAN
Department of General Surgery, Istanbul University Cerrahpaşa Medical Faculty, Istanbul

A rare PRSS1 mutation in a Turkish family with hereditary chronic pancreatitis

*Herediter kronik pankreatiti olan bir Türk ailedede nadir bir PRSS1 mutasyonu*

*To the Editor,*

Hereditary pancreatitis (HP) is an autosomal dominant-inherited disorder characterized by recurrent attacks of pancreatitis with the development of chronic pancreatitis in the absence of known etiologic factors (1,2). R122H and N29I mutations are the most common PRSS1 mutations that play a causal role in chronic pancreatitis worldwide (3-5). Herein, we report a rare PRSS1 mutation causing typical HP in a Turkish family. The polymorphism is called D21A and results in a substi-
tution of alanine by aspartic acid at amino acid position 21. To the best of our knowledge, there are few reports of a D21A polymorphism in patients with HP in the medical literature (6).

A 30-year-old male patient was admitted with acute abdominal pain radiating to the back, nausea and mild fever. Physical examination revealed abdominal tenderness in the epigastric region. The clinical history revealed many episodes during the previous five years, some treated at home. Laboratory tests were within normal ranges, except for high serum levels of serum amylase, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Abdominal ultrasound showed increased pancreatic volume with diffuse edema, and the biliary tree was normal. Based on the clinical and laboratory findings of the patient, the diagnosis of acute pancreatitis was made. In the follow-up of the patient with medical treatment, clinical and laboratory improvement was observed. Magnetic resonance imaging (MRI) of the pancreas was performed one month after discharge from the hospital. MRI showed chronic pancreatitis findings (pancreatic parenchymal calcifications, pancreatic ductal irregularities and dilatations). All the etiologic factors of chronic pancreatitis (alcohol, hypercalcemia, hyperlipidemia, obstructive, and autoimmune, etc.) were excluded. In his family history, his elder sister and his father had experienced recurrent attacks of pancreatitis as well. The family pedigree is shown in Figure 1. The sequencing analysis comprised the entire coding region of PRSS1, including the intron-exon boundaries of each exon, and was performed on an ABI 3100 genetic analyzer. All three patients were found to be heterozygotes for the D21A mutation in the PRSS1 gene. DNA isolated from peripheral blood samples was analyzed for CFTR gene mutations by the reverse-hybridization method using INNO-LiPA CFTR assay test strips, and no CFTR mutations were found.

In conclusion, in light of our case, D21A polymorphism in the cationic trypsinogen (PRSS1) gene seems to be a risk factor for HP. In addition to the most commonly seen R122H and N29I mutations, the D21A mutation should be kept in mind in patients presenting with chronic HP.

REFERENCES


Barış YILMAZ1, Fuat EKIZ2, Ekrem KARAKAŞ2, Ayça AYKUT2, Zahide ŞİMŞEK2, Şahin ÇOBAN2, Hüseyin ONAY2, Ferda ÖZKINAY2
Department of 1Gastroenterology, 2Deşhapa Yıldırım Beyazıt Educational and Research Hospital, Ankara
Department of 2Genetic, Ege University Medical School, Izmir
Department of 2Radiology, Harran University Medical School, Sanliurfa